MindPortal Raises $5 Million

MindPortal creators of the next personal computer that is a wearable non-invasive brain-computer interface, announced today it completed a $5 Million seed round of financing.

Learn Capital led the round, with additional investment from Kleiner Perkins; Dan Siroker, Founder & CEO of Scribe AI; Matt Bellamy, rockstar and frontman of Muse; James Park, Co-Founder & CEO of Fitbit; Julie Zhou, Co-Founder of Sundial and former Vice President of Product Design for Facebook; Scrum Ventures; and additional angels from frontier tech, hardware and product design. Previous pre-seed investors included 7pc and Y Combinator. The new funding will be used to hire additional neuroscientists, product engineers and machine learning experts.

Presently, MindPortal’s patent pending wearable device can record human brain activity in real time, without surgery, with 10-100x more precision than EEG technology. The platform brain computer being developed will act as a bi-directional portal; connecting the mind to immersive, creative and playful experiences and also as a gateway into the mind. When wearing MindPortal’s device, people will be able to create and share new experiences e.g. in VR/AR, just by using their thoughts, and channel experiences into their mind.

“We’re animated by a vision of the future where every human on the planet has a greater opportunity to fully develop their talents and minds,” said Rob Hutter, Founder & Managing Partner of Learn Capital. “MindPortal is pursuing what some would call the holy grail – namely, a portable and non-invasive platform that samples brain activity at high spatial and temporal resolution, a technical feat that could unleash the potential for a dramatic improvement in productivity across work, play and life.”

“All technology has been generated from the ingenuity of the human mind, but for the first time in the history of our species, we are turning that ingenuity towards creating technology that enhances the human mind itself,” Ekram Alam, Co-founder & CEO of MindPortal.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”